KALY Targets First $1 Million In Cannabis Extract Sales For Consumer Market
April 17 2019 - 02:15PM
InvestorsHub NewsWire
KALY Targets First $1 Million In Cannabis
Extract Sales For Consumer Market
Dallas, Tx -- April 17, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today published a presentation elaborating on
the company’s overall strategy to discover, develop and
commercialize novel therapeutics from its proprietary cannabinoid
product platform. In addition to detailing its cannabis
extracts biopharmaceutical strategy, the presentation includes
details on KALY’s parallel consumer market strategy separate from
the pharmaceutical industry. Management is targeting $1
million in sales outside the pharmaceutical space in 2019.
See the full presentation published today below.
Patented Cannabis Extracts
Targeting $170 In Million Pharmaceutical
Treatments
In the
fourth quarter of last year, 2018, KALY acquired NCM Biotech
(NCMB). NCMB is biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
a proprietary cannabinoid product platform in a broad range of
disease areas. In four years of operations, the company has
established a leading position in the development of plant-derived
cannabinoid therapeutics through a proven drug discovery and
patented development process. The resulting intellectual
property portfolio and the established regulatory and manufacturing
expertise have created a significant opportunity. KALY,
through its subsidiary, NCMB has a deep pipeline of additional
cannabinoid product candidates including four distinct
compounds. KALY has completed the first stage of clinical
development and testing for a Chronic Obstructive Pulmonary Disease
(COPD) therapy and is currently conducting phase one development
and trials for compounds targeting Cancer Pain Management, Type 2
Diabetes and Epilepsy.
$170 Million Cannabis Therapeutics Market
Opportunity
- Chronic
Obstructive Pulmonary Disease (COPD) - The market for COPD
treatment is anticipated to reach $14 billion by 2025;
- Type 2
Diabetes - The market for Type 2 Diabetes is expected to be a
$64 billion market by
2026;
- Cancer
Pain Management - The overall pain
management treatment market is anticipated to reach $83 billion by 2024, and
- Epilepsy
- The market for epilepsy
treatment is anticipated to reach $9 billion by 2022.
Cannabis Research
Methodology
KALY,
through its subsidiary NCMB focuses on the use of specific cannabis
extracts alone, and also along with using a proprietary process
which combines molecules of already proven therapeutic utility to
combat a variety of clinical disorders. In recognition of the
need to standardize candidate products and to determine mechanisms
for action with scientific credibility, KALY has established
collaborations with other companies and with universities to
enhance understanding and provide scientific support to the
introduction of novel cannabis extract formulations for the
consumer marketplace.
KALY has
already published its COPD research and initiated a second stage of
research and development. Research reports on the first phase
of development for KALY’s cannabis compounds for Type 2 Diabetes,
Cancer Pain Management and Epilepsy are expected to be published
later this year.
To
accelerate development, KALY is developing key partners with an
emphasis on establishing joint ventures with existing
biopharmaceutical companies. The company has a $3.5 million
development plan for its next stage of development and management
is working diligently to fund that development plan through the
capital structure of partner companies.
Beyond The Initial Four
Therapies
Beyond the
four specific cannabis therapies currently in various stages of
research and development, KALY has a number of additional target
therapies in its research pipeline. KALY’s proprietary extracts
have been evaluated in a genomic study where the extracts have
exhibited remarkable activity in gene arrays by up or down
regulating individual genes by as much as 200 fold. Genes
appearing especially sensitive to the introduction of KALY’s
cannabis extracts were associated with inflammation, healing and
cancer inhibition. The results of the genomic studies have
served to initiate planning for a host of additional therapies that
can be developed from KALY’s proprietary cannabis
extracts.
$1
Million 2019 Revenue Target From Parallel Revenue
Strategy
KALY is
not relying on its biopharmaceutical development strategy alone to
insure the company’s long-term success. With the popularity
of cannabis extracts for infusion into various consumer products,
KALY’s patented extraction process offers arguably the highest
quality extract to the infusion market. Drawing on KALY’s
patented cannabis extraction expertise, Puration’s EVERx CBD
Sports Water is already the leading CBD infused beverage for the
sports nutrition market. KALY has also introduced its own CBD
confections line, Hemp4mula with CBD infused gum already on the
market and gummies on the way. Hemp4mula is expected to be
available on the Ecommerce site USMJ.com hosted by North American Cannabis
Holdings, Inc. (USOTC:
USMJ) (aka USMJ). KALY has also entered into a
partnership with Nouveau , a cannabis cultivation company, with
plans to develop a proprietary cannabis cultivar that can further
enhance the quality of KALY’s extracts. KALY’s consumer
revenue strategy offers a business line that can stand alone, but
one that also provides KALY with the long-term staying power to
take the necessary time to bring its cannabis extract
biopharmaceutical products to market. Currently, KALY
management anticipates that its $1 million 2019 revenue goal for
its parallel consumer market strategy is well within
reach.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2023 to Mar 2024